Research Network for Metals in Medicine

 

 

Dr Laurence Morandeau

Position: Radiochemist

Affiliation: WA PET/Cyclotron Service

Postal Address:
Sir Charles Gairdner Hospital
Hospital Avenue
NEDLANDS WA 6009
AUSTRALIA

Phone: +61 (08) 9346 7495
Email: laurence.morandeau@health.wa.gov.au
Webpage: http://www.scgh.health.wa.gov.au/pet/laurence_morandeau.htm

Research Profile

Currently radiochemist Research and Development, Sir Charles Gairdner Hospital, Australia.

2002: Post-doctoral research officer in radiochemistry, Fremantle Hospital and Murdoch University Australia.

1999-2001: Institut National de la Santé et de la Recherche Médicale (INSERM)-Unit 463, 9 Quai Moncousu, Nantes, France - Synthesis of bivalent haptens coupled with bifunctional chelating agents, for applications to cancer radioimmunotherapy, with the Affinity Enhancement System.

1998: INSERM U463, Nantes, France - Organic chemistry project research.

1997: University of Nantes, France.

1994-1996: University of Le Mans, France.

1992-1994: Institut Universitaire de Technologie (I.U.T), Le Mans, France.Undergraduate studies. Training period in analytical chemistry, Ecotoxicology Department, University of Nantes, France.

Selected Publications

  1. Loussouarn A, Ouadi A, Morandeau L, Remaud P, Faivre-Chauvet A, Gestin J.F. "Influence of skeleton structure and group combinations on samarium-153 chelation capacity and stability."(Submitted)
  2. Loussouarn A, Ouadi A, Morandeau L, Remaud P, Giles R, Gestin J.F., Webb J."Synthesis of new semi-rigid chelating agents for samarium-153." Tetrahedron Letters, 2003, 44(17), 3539-3541.
  3. Supiot S, Faivre-Chauvet A, Couturier O, Heymann M, Robillard N, Kraeber-Bodéré F, Morandeau L, Mahé M, Chérel M. “Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma.” Cancer, February 15, 2002, 94 (4) Supp., 1202-1209
  4. Ouadi A, Loussouarn A, Remaud P, Morandeau L, Apostolidis C, Musikas C, Faivre-Chauvet A, Gestin J.F. “Synthesis of a novel bifunctional chelating agent for actinium complexation.” Tetrahedron Letters, 2000, 41(37), 7207-7209.
  5. Faivre-Chauvet A, Loussouarn A, Morandeau L, Gestin J.F, Chatal J.F. “Utilisation d’anticorps radiomarqués en cancérologie.” Actualités de Chimie thérapeutique, 1999, 251-271